Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Chimerix, Inc. (CMRX : NSDQ)

• Company Description    Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. Number of Employees: 87

• Price / Volume Information    Yesterday's Closing Price: $2.35 Daily Weekly Monthly 20 Day Moving Average: 4,174,082 shares Shares Outstanding: 87.44 (millions) Market Capitalization: $205.47 (millions) Beta: 1.28 52 Week High: $9.29 52 Week Low: $1.57 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -51.04% -44.86% 12 Week -57.19% -52.94% Year To Date -63.45% -58.19%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2505 MERIDIAN PARKWAY SUITE 100 - DURHAM,NC 27713 USA ph: 919-806-1074 fax: 919-806-1146 ir@chimerix.com http://www.chimerix.com

• General Corporate Information    Officers Michael T. Andriole - Chief Executive Officer; President and Director Martha J. Demski - Chairman of the Board of Directors Michael T. Andriole - Chief Business and Financial Officer David Jakeman - Executive Director of Finance and Accounting Catherine L. Gilliss - Directors Peer Information Chimerix, Inc. (BJCT) Chimerix, Inc. (CADMQ) Chimerix, Inc. (APNO) Chimerix, Inc. (UPDC) Chimerix, Inc. (IMTIQ) Chimerix, Inc. (CYGN) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 16934W106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 87.44 Most Recent Split Date: (:1) Beta: 1.28 Market Capitalization: $205.47 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.24 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $1.58 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: 1.49 Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.30 Price/Cash Flow: - Price / Sales: 367.58 EPS Growth vs. Year Ago Period: -55.56% vs. Previous Quarter: 37.78% Sales Growth vs. Year Ago Period: -98.95% vs. Previous Quarter: -67.39% ROE 03/31/22 - -118.41 12/31/21 - -84.90 09/30/21 - -58.06 ROA 03/31/22 - -90.18 12/31/21 - -67.01 09/30/21 - -47.77 Current Ratio 03/31/22 - 4.11 12/31/21 - 3.20 09/30/21 - 4.89 Quick Ratio 03/31/22 - - 12/31/21 - 3.11 09/30/21 - 4.83 Operating Margin 03/31/22 - -17,994.28 12/31/21 - -4,565.23 09/30/21 - -2,047.92 Net Margin 03/31/22 - -17,994.28 12/31/21 - -8,753.71 09/30/21 - -4,762.96 Pre-Tax Margin 03/31/22 - -17,994.27 12/31/21 - -8,753.71 09/30/21 - -4,762.96 Book Value 03/31/22 - 0.55 12/31/21 - 0.79 09/30/21 - 1.21 Inventory Turnover 03/31/22 - 0.06 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Equity 03/31/22 - 0.01 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.52 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©